Drugs / SLV-154
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06771219 | May 2025 → Jan 2027 expected | breast carcinoma, cervical cancer, endometrial cancer, head and neck squamous cell carcinoma +6 | Solve Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SLV-154 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06771219 ↗ |
| Route | Intravenous | “SLV-154 will be administered intravenously (IV) in repeated 3-week cycles.” NCT06771219 ↗ |